No Data
No Data
Pinning Down Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) P/E Is Difficult Right Now
It's not a stretch to say that Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) price-to-earnings (or "P/E") ratio of 7.7x right now seems quite "middle-of-the-road"
Statistics of capital trend for the Connect of China-HK Stock Connect(T+2) on July 16th.
Capital trend of ChiNext Stock Connect on July 16th.
Baiyunshan (00874): Injection-grade ceftriaxone sodium has passed the evaluation of generic drug quality and efficacy consistency.
Zhixing Finance APP News, on July 11, 2024, Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory (hereinafter referred to as the "Baiyunshan Pharmaceutical Factory") received the drug supplementary application approval notification issued by the State Drug Administration for the injection of cephalosporin sodium, which has passed the consistency evaluation of generic drugs in terms of quality and efficacy.
Baiyunshan (600332.SH): The subsidiary's pharmaceutical cefuroxime sodium for injection passed the generic consistency evaluation.
On July 12th, Gelonhui reported that Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., a subsidiary of Baiyunshan (600332.SH), Baiyunshan Pharmaceutical Factory (referred to as Baiyunshan Pharmaceutical Factory), received the drug supplementary application approval notification issued by the State Drug Administration for injection ceftriaxone sodium, which has passed the consistency evaluation of generic drug quality and efficacy. Ceftriaxone sodium is a second-generation cephalosporin that is sensitive to most gram-negative and gram-positive bacteria, and has the advantages of a broad antibacterial spectrum, low renal toxicity, and stability to β-lactamase. It is widely used in clinical treatment of respiratory tract infections, urinary system infections, and more.
Guangzhou Baiyunshan Pharmaceutical Secures Drug Registration for Erectile Dysfunction Tablets
Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) received the drug registration certificate for its erectile dysfunction drug, tadalafil tablets, from the State Drug Administration. The drug
Baiyunshan (600332.SH): Tadalafil tablets have received pharmaceutical registration certificate.
On June 26th, Gelunhui reported that Guangzhou Baiyunshan Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan (600332.SH), received the Drug Registration Certificate issued by the National Medical Products Administration for Tadalafil Tablets (20mg) from Baiyunshan Pharmaceutical Factory. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor mainly used for the treatment of male erectile dysfunction (ED).
No Data